Regeneron (REGN) Tops Q1 EPS by 35c, Updates FY Guidance

May 3, 2018 6:31 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Regeneron (NASDAQ: REGN) reported Q1 EPS of $4.67, $0.35 better than the analyst estimate of $4.32. Revenue for the quarter came in at $1.51 billion versus the consensus estimate of $1.51 billion.

2018 Financial Guidance(3)

The Company's updated full year 2018 financial guidance consists of the following components:

Sanofi collaboration revenue: Sanofi reimbursement of Regeneron commercialization-related expenses

$450 million–$485 million

(previously $450 million–$500 million)

Non-GAAP unreimbursed R&D(2)(4)

$1.230 billion$1.310 billion

(previously $1.230 billion–$1.330 billion)

Non-GAAP SG&A(2)(4)

$1.325 billion–$1.395 billion

(previously $1.350 billion–$1.450 billion)

Effective tax rate


(previously 15%–19%)

Capital expenditures

$420 million$480 million

(previously $420 million–$500 million)

For earnings history and earnings-related data on Regeneron (REGN) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities